These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35270034)

  • 21. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
    Klotz DM; Wimberger P
    Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    Suzuki Y; Wenwen W; Ohta T; Hayashi SI
    Breast Cancer; 2022 Jan; 29(1):77-91. PubMed ID: 34346034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    Moore KN; Pothuri B
    Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 26. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL-6-STAT3 signalling.
    Chi L; Huan L; Zhang C; Wang H; Lu J
    J Cell Mol Med; 2023 Aug; 27(15):2150-2164. PubMed ID: 37278400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    Miller RE; El-Shakankery KH; Lee JY
    J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
    Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
    Bhattacharjee S; Sullivan MJ; Wynn RR; Demagall A; Hendrix AS; Sindhwani P; Petros FG; Nadiminty N
    BMC Cancer; 2022 Mar; 22(1):312. PubMed ID: 35321693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
    Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
    Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of PARP Inhibitor Resistance.
    O'Connor MJ; Forment JV
    Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.